AZRX AzurRx BioPharma, Inc. Stock Quote

AZRX [NASD]

Index	-	P/E	-	EPS (ttm)	-0.88	Insider Own	11.09%	Shs Outstand	49.44M	Perf Week	-3.98%
Market Cap	87.66M	Forward P/E	-	EPS next Y	-0.43	Insider Trans	0.00%	Shs Float	29.48M	Perf Month	-22.12%
Income	-24.70M	PEG	-	EPS next Q	-0.14	Inst Own	5.00%	Short Float	7.71%	Perf Quarter	118.06%
Sales	-	P/S	-	EPS this Y	22.80%	Inst Trans	17.70%	Short Ratio	0.29	Perf Half Y	109.65%
Book/sh	0.49	P/B	3.45	EPS next Y	50.60%	ROA	-243.00%	Target Price	-	Perf Year	101.12%
Cash/sh	0.22	P/C	7.69	EPS next 5Y	-	ROE	-472.30%	52W Range	0.37 - 2.63	Perf YTD	74.23%
Dividend	-	P/FCF	-	EPS past 5Y	-22.50%	ROI	-	52W High	-35.74%	Beta	1.72
Dividend %	-	Quick Ratio	4.40	Sales past 5Y	-	Gross Margin	-	52W Low	355.69%	ATR	0.26
Employees	10	Current Ratio	4.40	Sales Q/Q	-	Oper. Margin	-	RSI (14)	55.41	Volatility	11.81% 14.37%
Optionable	No	Debt/Eq	0.00	EPS Q/Q	-181.20%	Profit Margin	-	Rel Volume	0.32	Prev Close	1.48
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	7.82M	Price	1.69
Recom	2.20	SMA20	1.78%	SMA50	38.07%	SMA200	79.95%	Volume	2,477,110	Change	14.19%

Jan-06-21

Downgrade

Dawson James

Buy → Neutral

Jun-11-19

Initiated

National Securities

Buy

Oct-17-18

Initiated

Oppenheimer

Outperform

Jul-24-17

Initiated

H.C. Wainwright

Buy

Feb-24-21 07:00AM	AzurRx BioPharma Appoints President and CEO James Sapirstein as New Chairman of the Board of Directors GlobeNewswire +14.19%
Feb-16-21 07:00AM	AzurRx BioPharma to Present at The Microcap Rodeo Winter Wonderland Conference GlobeNewswire
Feb-09-21 06:30AM	AzurRx BioPharma Engages PPD to Manage Clinical Trial for Niclosamide as Treatment for COVID-19 Gastrointestinal Infections GlobeNewswire +7.69%
Feb-08-21 08:00AM	AzurRx BioPharma to Present at BIO CEO & Investor Digital Conference GlobeNewswire +9.74%
Jan-28-21 07:00AM	AzurRx BioPharma Announces Completion of Enrollment in First Cohort of Phase 2b OPTION 2 Extension Study of MS1819 GlobeNewswire -8.54%
Jan-26-21 07:00AM	AzurRx BioPharma Adds Two New Clinical Trial Sites in Europe for Phase 2b OPTION 2 Extension Study of MS1819 Immediate-Release Capsules in Cystic Fibrosis Patients GlobeNewswire -8.29%
Jan-22-21 10:18AM	AzurRx (AZRX) Starts Dosing in Pancreatic Insufficiency Study Zacks +48.39%
Jan-21-21 10:34AM	2 Strong Buy Penny Stocks That Could See Outsized Gains TipRanks +34.55%
08:00AM	AzurRx BioPharma Announces First Two Patients Dosed in Phase 2b OPTION 2 Extension Study of MS1819 in Cystic Fibrosis Patients GlobeNewswire
Jan-12-21 08:30AM	AzurRx BioPharma and First Wave Bio Announce Allowance of U.S. Patent Application for Niclosamide as Treatment for COVID-19 Gastrointestinal Infections GlobeNewswire
Jan-08-21 09:00AM	AzurRx BioPharma CEO Issues Letter to Shareholders GlobeNewswire
Jan-07-21 08:00AM	AzurRx BioPharma to Participate in Biotech Showcase Digital 2021 Conference GlobeNewswire
Jan-06-21 08:00AM	AzurRx BioPharma to Participate in H.C. Wainwright BioConnect 2021 Virtual Conference GlobeNewswire
Jan-05-21 08:00AM	AzurRx BioPharma to Participate in 10th Annual LifeSci Partners Corporate Access Event GlobeNewswire -5.56%
Jan-04-21 07:00AM	AzurRx BioPharma Announces Exclusive Worldwide License Agreement with First Wave Bio for Use of Proprietary Niclosamide Formulations to Treat Immune Checkpoint Inhibitor-Associated Colitis and COVID-19 Gastrointestinal Infections GlobeNewswire -7.22%
07:00AM	AzurRx BioPharma Announces $8.0 Million Offerings GlobeNewswire
Nov-30-20 08:00AM	AzurRx BioPharma Announces First Patients Dosed in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency GlobeNewswire
Nov-24-20 08:17AM	InvestorBrandNetwork (IBN) Announces Latest Episode of Stock2Me Podcast Featuring AzurRx Biopharma Inc. President & CEO James Sapirstein GlobeNewswire
Nov-17-20 08:00AM	AzurRx BioPharma Requests Protocol Amendment to Phase 2b OPTION 2 Study of MS1819 in Cystic Fibrosis Patients GlobeNewswire
Nov-10-20 08:00AM	AzurRx BioPharma Identifies Asymchem as Potential Partner of Choice for MS1819 Phase 3 Clinical Trial Drug Production GlobeNewswire
Oct-29-20 12:05PM	AzurRx BioPharma Provides Insight into Drawbacks of Using Porcine Products in Production of Pharmaceuticals and Medicinals, Offers Update on Efforts to Produce Synthetic Alternatives GlobeNewswire -5.05%
Oct-21-20 08:00AM	AzurRx BioPharma Announces Formation of Scientific Advisory Board GlobeNewswire
Oct-14-20 08:00AM	AzurRx BioPharma Activates Additional Clinical Trial Sites in Turkey for Phase 2 Combination Therapy Trial of MS1819 in Cystic Fibrosis GlobeNewswire
Oct-07-20 08:00AM	AzurRx BioPharma CEO Issues Letter to Shareholders GlobeNewswire
Sep-15-20 08:00AM	AzurRx BioPharma Announces Two Abstracts Accepted for Presentation at the 2020 North American Cystic Fibrosis Virtual Conference GlobeNewswire +6.94%
Aug-31-20 06:12PM	LD Micro: 360 Companies - Set to Present this Week ACCESSWIRE
08:00AM	AzurRx BioPharma to Present at the 2020 H.C. Wainwright 22nd Annual Global Investment Conference (September 14) and the LD 500 Virtual Conference (September 4) GlobeNewswire
Aug-26-20 06:42AM	AZRX: 1H:21 Readout for OPTION 2 and Combo Trials Zacks Small Cap Research -5.66%
Aug-17-20 08:00AM	AzurRx BioPharma Initiates European Arm of Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis GlobeNewswire
Aug-13-20 08:00AM	AzurRx BioPharma Announces First Patients Dosed in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis GlobeNewswire -12.39%
Aug-12-20 03:43PM	AzurRx BioPharma CEO Issues Clarifying Statement to Shareholders GlobeNewswire +9.88%
12:20PM	AZRX: MS1819 Update: Interim Data Zacks Small Cap Research
07:29AM	The Daily Biotech Pulse: India Globalization Gets Nod For Alzheimer's Trial, Moderna's Vaccine Deal With US, Cellular Biomedicine To Go Private Benzinga
Aug-11-20 04:01PM	AzurRx BioPharma Announces Positive Interim Data From First Patient Cohort in Phase 2 Clinical Trial of MS1819 in Combination with PERT Therapy in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency GlobeNewswire +7.97%
Aug-05-20 11:04AM	LD Micro Announces Preliminary List of Presenters for the LD-500. ACCESSWIRE
Jul-27-20 05:22AM	AZRX: Capital Raise, OPTION 2 Trial Underway Zacks Small Cap Research
Jul-22-20 08:20AM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating AzurRx BioPharma, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors PR Newswire +9.52%
08:00AM	AzurRx BioPharma Initiates Phase 2b Clinical Trial of MS1819 in Cystic Fibrosis with First Patient Screened and Three Clinical Trial Sites Activated GlobeNewswire
Jul-21-20 08:00AM	Alexander Capital, L.P. Congratulates AzurRx BioPharma on $15.2 Million Private Placement and $6.9 Million Convertible Note Exchange GlobeNewswire +8.25%
Jul-20-20 08:00AM	AzurRx BioPharma Closes $15.2 Million Private Placement and $6.9 Million Convertible Note Exchange GlobeNewswire
Jun-01-20 05:45AM	AZRX: Next Up: OPTION 2 Zacks Small Cap Research
May-29-20 03:08PM	Here is What Hedge Funds Think About AzurRx BioPharma, Inc. (AZRX) Insider Monkey
May-07-20 08:00AM	AzurRx BioPharma Announces Entry into Packaging, Labeling and Distribution Agreement with Creapharm Clinical Supplies for MS1819 Clinical Trial Drug Product GlobeNewswire
May-05-20 08:00AM	AzurRx BioPharma Receives Approximately $721,000 for its 2019 CIR (French Research Tax Credit) GlobeNewswire
May-04-20 06:45AM	What Kind Of Share Price Volatility Should You Expect For AzurRx BioPharma, Inc. (NASDAQ:AZRX)? Simply Wall St. +8.30%
Apr-30-20 08:00AM	AzurRx BioPharma Receives Insititutional Review Board Approval to Commence its Phase 2 OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis GlobeNewswire
Apr-29-20 08:00AM	AzurRx BioPharma Receives Approval to Conduct its Phase 2 OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis Therapeutics Development Network Sites GlobeNewswire
Apr-21-20 08:00AM	AzurRx BioPharma Issues Letter to Shareholders GlobeNewswire -9.16%
Apr-20-20 08:00AM	Argus Research Initiates Equity Research Report Coverage on AzurRx BioPharma, Inc. (NasdaqCM: AZRX) GlobeNewswire
Apr-16-20 02:00PM	AzurRx Announces Manufacturing Agreement with Delpharm for MS1819 Clinical Drug Product GlobeNewswire +17.24%
Apr-15-20 08:00AM	AzurRx BioPharma to Present at the Planet MicroCap Showcase Virtual Investor Conference 2020 ACCESSWIRE -6.45%
Apr-09-20 10:30AM	AzurRx Appoints Gregory Oakes to its Board of Directors GlobeNewswire +8.93%
06:50AM	AZRX: Tax Credits Augment Cash Flow Zacks Small Cap Research
Apr-01-20 12:00PM	AzurRx BioPharma Receives $642,000 for its 2017 CIR (French Research Tax Credit) GlobeNewswire
Mar-18-20 08:00AM	AzurRx BioPharma to Present at the New York City based Investor Summit on March 25th-26th ACCESSWIRE
Mar-02-20 08:00AM	AzurRx BioPharma Receives $1.13 million in 2018 CIR (French Research Tax Credit) GlobeNewswire -5.08%
Feb-18-20 08:00AM	AzurRx BioPharma Announces Presentation of Phase II MS1819 Data in Cystic Fibrosis at the 2020 Digestive Disease Week Conference GlobeNewswire
Feb-03-20 10:10AM	AZRX: EPI Treatment in the News Zacks Small Cap Research +9.99%
Jan-13-20 08:00AM	AzurRx BioPharma Announces Closing of $6.9 Million Private Placement GlobeNewswire
Jan-12-20 05:05PM	The Week Ahead In Biotech: JPMorgan Healthcare Conference, FDA Panel Reviews Opioid Pain Drugs, I-Mab's IPO Benzinga
Jan-09-20 07:22PM	AzurRx BioPharma To Present Interim Phase 2 Clinical Study Data for MS1819-SD, in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency, at Biotech Showcase 2020 Conference (January 13) in San Francisco GlobeNewswire +18.33%
Jan-06-20 08:00AM	AzurRx BioPharma to Present at the Biotech Showcase 2020 Conference (January 13th) GlobeNewswire
Jan-03-20 08:00AM	AzurRx BioPharma Announces Appointment of Daniel Schneiderman as Chief Financial Officer GlobeNewswire
Nov-26-19 11:35AM	AZRX: 3Q:19 Review Zacks Small Cap Research -5.07%
Nov-14-19 08:00AM	AzurRx BioPharma, Inc. Announces Equity Purchase Agreement for up to $15 Million with Lincoln Park Capital Fund, LLC GlobeNewswire +26.98%
Oct-22-19 08:00AM	AzurRx BioPharma CEO Issues Letter to Shareholders GlobeNewswire
Oct-17-19 12:30PM	AzurRx BioPharma Announces Positive CFF DSMB Review of Final Phase 2 OPTION Trial Data GlobeNewswire +24.71%
Oct-15-19 07:30AM	AzurRx BioPharma Announces First Patients Dosed in Clinical Study for MS1819-SD in combination with PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency GlobeNewswire +23.36%
Oct-10-19 07:30AM	AzurRx BioPharma Announces Appointment of James Sapirstein as Chief Executive Officer GlobeNewswire -9.94%
Sep-27-19 08:30AM	AZRX: OPTION Trial Readout Zacks Small Cap Research -11.06%
Sep-25-19 08:57AM	AzurRx Shares Tank On Unimpressive Efficacy Data For Biologic Drug To Treat Pancreatic Insufficiency Benzinga -21.00%
07:30AM	AzurRx BioPharma Announces Positive Results from Phase 2 Trial with MS1819 in Cystic Fibrosis Patients GlobeNewswire
Aug-28-19 01:15PM	What Kind Of Shareholder Owns Most AzurRx BioPharma, Inc. (NASDAQ:AZRX) Stock? Simply Wall St.
Aug-26-19 11:30AM	AZRX: OPTION & Combo Trial Underway Zacks Small Cap Research
Aug-13-19 07:00AM	AzurRx BioPharma Reports Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Jul-22-19 08:01PM	AzurRx BioPharma Announces Closing of $5.0 Million Public Offering of Common Stock ACCESSWIRE
Jul-17-19 11:35PM	AzurRx BioPharma Announces Pricing of $5.0 Million Public Offering of Common Stock ACCESSWIRE
04:44PM	AzurRx BioPharma Announces Proposed Public Offering of Common Stock GlobeNewswire
Jul-10-19 10:45AM	AZRX: Launch of Study for Cystic Fibrosis Patients With Severe EPI Zacks Small Cap Research +5.69%
Jul-08-19 04:03PM	AzurRx BioPharma Announces R&D Update Call on Monday, July 8th at 4:30 PM ET GlobeNewswire -13.79%
04:01PM	AzurRx BioPharma Announces Initiation of Phase 2 Clinical Study for MS1819-SD in combination with standard PERT for Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency GlobeNewswire
Jun-07-19 08:00AM	AzurRx BioPharma Announces Notice of Allowance of U.S. and Japan Patents Covering a MTAN Inhibitor for Treating H. Pylori Infections, the Primary Cause of Stomach Ulcers GlobeNewswire
May-28-19 08:22AM	How Many AzurRx BioPharma, Inc. (NASDAQ:AZRX) Shares Did Insiders Buy, In The Last Year? Simply Wall St.
May-23-19 09:45AM	AZRX: Secondary Endpoint Data Released for MS1819-SD in Chronic Pancreatitis Patients Zacks Small Cap Research
08:00AM	AzurRx BioPharma Reaches Enrollment Target for Phase II OPTION Clinical Trial GlobeNewswire
May-20-19 02:30PM	AzurRx BioPharma Presents Positive Secondary Endpoint Data in its Phase II MS1819-SD Chronic Pancreatitis Study at the 2019 Digestive Disease Week Conference GlobeNewswire
Apr-23-19 07:45AM	AzurRx BioPharma Exceeds 50% Enrollment Target for Phase II OPTION Clinical Trial GlobeNewswire
Apr-11-19 10:00AM	AZRX: CF Study Up and Enrolling; Target to $8 Zacks Small Cap Research
Apr-02-19 07:45AM	Expanded MS1819-SD Global Commercialization Rights Now Owned by AzurRx BioPharma along with Full Development Rights GlobeNewswire
Mar-18-19 07:45AM	AzurRx BioPharma Announces Presentation on Its Positive Phase II Data in MS1819-SD in Chronic Pancreatitis at the 2019 Digestive Disease Week Conference GlobeNewswire
Mar-15-19 07:45AM	AzurRx BioPharma to Present at the 2019 Annual Roth Capital Conference (March 19) and the Oppenheimer 29th Annual Healthcare Conference (March 20) GlobeNewswire +7.37%
Mar-12-19 07:45AM	AzurRx BioPharma Announces Poster Presentation at the Americas Hepato-Pancreato-Biliary Association 2019 Annual Meeting GlobeNewswire
Feb-20-19 07:45AM	AzurRx BioPharma Announces First Patients Dosed in Phase II OPTION Clinical Trial GlobeNewswire +18.24%
Jan-21-19 11:52AM	What Kind Of Shareholder Owns Most AzurRx BioPharma, Inc. (NASDAQ:AZRX) Stock? Simply Wall St.
Dec-19-18 08:00AM	AzurRx BioPharma Announces Initiation of Phase II OPTION Clinical Trial of MS1819-SD in Cystic Fibrosis Patients GlobeNewswire
Dec-12-18 08:00AM	AzurRx BioPharma to Acquire Payment Rights to Lead Drug Candidate MS1819-SD from Protea Biosciences Group GlobeNewswire
Dec-04-18 09:45AM	AZRX: 3Q:18 Financial and Operational Summary Zacks Small Cap Research
08:00AM	AzurRx BioPharma to Present at Upcoming Investor Conferences GlobeNewswire
Nov-01-18 07:30AM	AzurRx BioPharma Receives Sanction of Cystic Fibrosis Therapeutics Development Network for the Study of MS1819-SD in CF Patients with EPI GlobeNewswire +8.60%
Oct-16-18 07:30AM	AzurRx BioPharma Announces FDA Acceptance of IND Application for Phase 2 Clinical Trial of MS1819-SD in Patients with Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis GlobeNewswire

AzurRx BioPharma, Inc., a clinical stage biopharmaceutical company, focuses on the development of recombinant proteins for the treatment of gastrointestinal diseases. Its therapeutic products administer patients as oral non-systemic biologics. The company's lead therapeutic is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (for cystic fibrosis and chronic pancreatitis patients). It is also developing two clinical programs using proprietary formulations of niclosamide, a pro-inflammatory pathway inhibitor, including FW-420, for grade 1 Immune Checkpoint Inhibitor-associated colitis and diarrhea in oncology patients; and FW-1022, for COVID-19 gastrointestinal infections. The company was incorporated in 2014 and is headquartered in Delray Beach, Florida with scientific operations in Langlade, France and clinical operations in Hayward, California.

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience